Zynerba's cannabis-based gel succeeds in mid-stage study
(Reuters) - Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel succeeded in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Disability | Fragile X Syndrome | Genetics | Health | Learning | Study | Universities & Medical Training